Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk CEO defending GLP-1 pricing and the push to lower prices.

Evan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate hearing today about the prices of Ozempic and Wegovy.

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

The new Lemme GLP-1 Daily Capsules are being called an "Ozempic alternative." But do they really work — and if so, at what ...

Novo Nordisk's CEO faced lawmakers in a grueling 2.5-hour hearing to discuss the cost of blockbuster drugs Ozempic and Wegovy ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

Natural supplements have “very mild effects” on weight loss based on what Dr. Ali has seen. There is some data to suggest ...

Glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are entero-pancreatic hormone-based treatments first approved in 2005 for type 2 diabetes (T2D). They are now commonly prescribed for weight ...